Elevate TN:
6-year follow up data showing significant superiority in PFS vs OClb2,3
In previously untreated patients, CALQUENCE as monotherapy demonstrated PFS benefit vs OClb, so with 62% progression-free at 6 years (exploratory analysis)
Please see the About Calquence section and the individual study sections for information on safety
Elevate R/R:
Efficacy and safety profile
of acalabrutinib vs ibrutinib1
In relapsed/refractory patients, CALQUENCE demonstrated non-inferior efficacy to ibrutinib, with significantly lower incidence of atrial fibrillation/flutter
Atrial fibrillation/flutter is listed as a special warning in the SmPC
Please see the About Calquence section and the individual study sections for information on safety
ASCEND:
Improved PFS including in high risk patients vs IdR or BR5,8
CALQUENCE was the first BTKi monotherapy to demonstrate improved PFS vs IdR/BR in relapsed/refractory CLL
Please see the About Calquence section and the individual study sections for information on safety
Got a
question?
Enter your details to have someone
from AstraZeneca contact you
Abbreviations:
BR, bendamustine + rituximab; BTKi, Bruton tyrosine kinase inhibitor; CLL, chronic lymphocytic leukaemia; IdR, idelalisib + rituximab; OClb, obinutuzumab + chlorambucil; PFS, progression-free survival; SOC, standard of care.
References:
1. Byrd JC, et al. J Clin Oncol. 2021;39(31):3441–3452. 2. Sharman P, et al. (Blood. 2023; 142(1):636. 3. Sharman JP, et al. Presented at the American Society of Haematology (ASH) Annual Meeting; December 9-12, 2023. Presentation #636 4. Eichhorst B, et al. Ann Oncol. 2021;32(1):23–33. 5. Ghia P, et al. J Clin Oncol. 2020;38(25):2849–2861. 6. Calquence Summary of Product Characteristics. 7. Walewska R, et al. Br J Haematol. 2022;197:544–557. 8. Ghia P, et al. Hemasphere 2022; 6(12): e801.
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
May 2025 │ GB-54981